Ascendis Pharma A/S
ASND166.780USD
+3.460+2.12%
Handelsschluss 07/30, 16:00（ET）Kurse um 15 Minuten verzögert
10.17BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ascendis Pharma A/S Unternehmen
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Unternehmensinformationen
BörsenkürzelASND
Name des UnternehmensAscendis Pharma A/S
IPO-datumJan 28, 2015
Gegründet am2006
CEOMr. Jan Moller Mikkelsen
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeJan 28
AddresseTuborg Boulevard 12
StadtHELLERUP
BörseNASDAQ Global Select Consolidated
LandDenmark
Postleitzahl2900
Telefon4570222244
Websitehttps://ascendispharma.dk/
BörsenkürzelASND
IPO-datumJan 28, 2015
Gegründet am2006
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Umsatzaufteilung
Währung: EURAktualisiert: Sun, Jul 6
Währung: EURAktualisiert: Sun, Jul 6
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Commercial sale of products
96.03M
95.12%
Rendering of services
3.52M
3.49%
License
1.40M
1.39%
Nach RegionEUR
Name
Umsatz
Anteil
North America
73.69M
72.99%
Europe
21.33M
21.13%
Rest of world
5.94M
5.88%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Commercial sale of products
96.03M
95.12%
Rendering of services
3.52M
3.49%
License
1.40M
1.39%
Aktionärsstatistik
Aktualisiert: Wed, Jul 23
Aktualisiert: Wed, Jul 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
17.03%
Westfield Capital Management Company, L.P.
9.08%
Avoro Capital Advisors LLC
8.64%
Janus Henderson Investors
7.43%
Fidelity Management & Research Company LLC
7.13%
Other
50.69%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
17.03%
Westfield Capital Management Company, L.P.
9.08%
Avoro Capital Advisors LLC
8.64%
Janus Henderson Investors
7.43%
Fidelity Management & Research Company LLC
7.13%
Other
50.69%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
41.95%
Investment Advisor
39.74%
Venture Capital
17.38%
Hedge Fund
8.82%
Research Firm
4.70%
Individual Investor
0.78%
Family Office
0.44%
Family Office
0.44%
Pension Fund
0.36%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
494
68.89M
114.11%
-2.99M
2025Q1
513
68.89M
114.10%
-3.55M
2024Q4
488
67.37M
111.00%
-7.76M
2024Q3
475
65.25M
107.66%
-6.23M
2024Q2
459
63.44M
108.94%
-9.21M
2024Q1
453
63.54M
109.13%
-8.68M
2023Q4
430
62.90M
109.00%
-9.55M
2023Q3
414
62.85M
109.61%
-11.90M
2023Q2
426
63.03M
109.93%
-13.27M
2023Q1
427
63.10M
110.08%
-9.14M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
10.28M
17.03%
+168.75K
+1.67%
Mar 31, 2025
Westfield Capital Management Company, L.P.
5.48M
9.08%
-48.98K
-0.89%
Mar 31, 2025
Avoro Capital Advisors LLC
5.22M
8.64%
+114.94K
+2.25%
Mar 31, 2025
Janus Henderson Investors
4.49M
7.43%
+106.57K
+2.43%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.30M
7.13%
-52.57K
-1.21%
Mar 31, 2025
Artisan Partners Limited Partnership
4.26M
7.05%
-193.79K
-4.35%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.05M
5.06%
+328.28K
+12.04%
Mar 31, 2025
Capital International Investors
2.87M
4.76%
+11.54K
+0.40%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.26M
3.74%
-27.11K
-1.19%
Mar 31, 2025
MFS Investment Management
1.87M
3.1%
+9.63K
+0.52%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Harbor Health Care ETF
18.34%
AdvisorShares Dorsey Wright ADR ETF
2.58%
American Century Focused Dynamic Growth ETF
2.27%
BNY Mellon Innovators ETF
2.26%
Virtus LifeSci Biotech Products ETF
2.01%
Tema Heart & Health ETF
1.25%
ProShares Ultra Nasdaq Biotechnology
1.19%
Invesco Nasdaq Biotechnology ETF
1.11%
Main Thematic Innovation ETF
0.76%
Putnam Sustainable Future ETF
0.75%
Mehr Anzeigen
Harbor Health Care ETF
Anteil18.34%
AdvisorShares Dorsey Wright ADR ETF
Anteil2.58%
American Century Focused Dynamic Growth ETF
Anteil2.27%
BNY Mellon Innovators ETF
Anteil2.26%
Virtus LifeSci Biotech Products ETF
Anteil2.01%
Tema Heart & Health ETF
Anteil1.25%
ProShares Ultra Nasdaq Biotechnology
Anteil1.19%
Invesco Nasdaq Biotechnology ETF
Anteil1.11%
Main Thematic Innovation ETF
Anteil0.76%
Putnam Sustainable Future ETF
Anteil0.75%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
